In the Name of God. Screening of Cervical Cancer Pap smear and colposcopy F.Behnamfar Gynecology Oncology Fellowship Associate Professor Isfahan University.

Slides:



Advertisements
Similar presentations
Cervical Screening Guidelines - for now and the future - Meg McLachlin, MD, FRCPC.
Advertisements

Cervical Cancer and Vaccines
Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University.
MANAGEMENT OF ABNORMAL PAP SMEAR
MANAGEMENT OF THE ABNORMAL PAP SMEAR
Cervical Cancer. Dr. Swapna Chaudhary M.S. (MUM) Consultant Obstetrician & Gynaecologist Infertility Specialist.
Updates on Pap Smear Guidelines 2014
Speaker: Decca Mohammed, MD.  Statistics for cervical cancer and HPV  Association of HPV to cervical cancer, and other cancers  Prevention  Screening.
Evolution of Neoplasia The Uterine Cervix As a Model Raj C. Dash, MD Duke University Medical Center Durham, North Carolina.
ASHLYN SAVAGE, MD, MSCR ASSOCIATE PROFESSOR OBSTETRICS AND GYNECOLOGY MEDICAL UNIVERSITY OF SOUTH CAROLINA Managing Abnormal Pap Smears: Incorporating.
Sample Taker Training Cervical Cytology & Management of Abnormalities.
COLPOSCOPY RANDOM CERVICAL BIOPSIES ENDOCERVICAL CURETTAGE S.C.P.M.G.-Fontana.
Cervix Dr. Raid Jastania. Cervical Cancer Screening HPV infection Pre- Cancerous Dysplasia Cancer years.
Cervical Cancer Cervical dysplasia Cervical cancer Causes Risk factors
HPV and cervical screening Test of cure
Screening for Cervical Cancer
Management of Women with CIN 1 or LSIL
Benign and premalignant disease of the cervix
Cervical Cancer: Prevention and Treatment
Jacqueline Castagno, MD FACOG Division of Gynecologic Oncology Department of Obstetrics and Gynecology University of Florida College of Medicine.
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
Case Presentations: Pre-Invasive Cervical Neoplasia
HPV: How to prevent your patients from becoming my patients Katina Robison, MD Assistant Professor, Department of Obstetrics & Gynecology Director of Colposcopy.
Cervical Cancer Screening
Screening Tests for Brest & Cervical Cancer
Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.
CANCER CERVIX A PREVENTABLE CANCER Dr NEETA DHABHAI Sr Consultant. – Gynaecologist Member Expert - Indian Cancer Winners’ Association
Cervical Cancer in California Janet Bates, MD MPH Research Program Director Research and Surveillance Program California Cancer Registry.
Cervical Cancer Screening and HPV
Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.
Cervical Cancer Screening Recommendations 2012, FDA Panel 2014.
Abnormal Pap in Pregnancy Alexander Burnett, MD Division Gyn Oncology, UAMS April, 2006.
SoftPAP® A Novel Collection Device for Cervical Cytology.
Screening for Cervical Cancer Dr. Shanthi Manivannan, MD.
Screening for cervical cancer. Screening for cervical lesions Common disease Cancer is preventable Screening is easy MUST BE PERFORMED.
Current guidelines for Cervical Cancer Screening
Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Screening.
CERVICAL/VAGINAL CYTOLOGY
Cervical Intraepithelial Neoplasm
Top Pap smear Questions. 1-When should Pap screening begin? Age 21 y/o,3yrs after first intercourse.
HspE7 INFECTIOUS DISEASE VACCINE FOR THE TREATMENT OF CERVICAL CARCINOMA.
Gynecologic Cytopathology
Premalignant lesions of the cervix. Applied anatomy.
What is a Pap smear? is a medical procedure in which a sample of cells from a woman's cervix is collected and spread (smeared) on a microscope slide.
COLPOSCOPY QUESTIONS Michael R. Downs M.D. October 2004.
2006 ASCCP Consensus Guidelines Anne L. Kittendorf, MD FAAFP Assistant Professor University of Michigan Department of Family Medicine.
HPV and Pap Guidelines Jennifer Johnson MD. Objectives 1. Define the new PAP guidelines. 2. Identify the historical trends and new evidence resulting.
Treatment for Cervical Cancer
To pap or not to pap: and what to do when you do Kimberly Swan MD Minimally Invasive Gynecologic Surgery Assistant Professor Ob/Gyn University of Kansas.
HPV-related anogenital cancers
Cytopathology Feb
Morphologic Pap Test Findings in HPV Negative Women Age 30 Years and Older: What Information Will Be Lost with HPV Only Primary Screening? Brooke Henninger,
Chapter 29 Human Papilloma Virus Infection and Immunity.
Cervical Cancer Screening NURS 541: Women’s Healthcare – Diagnosis and Management.
THE NEW CERVICAL CANCER SCREENING PROGRAM
Trreatment of Preinvasive Lesions
Cervical Cancer Colposcopy & Treatment
Risk factors for cervical intraepithelial neoplasia recurrence after loop electrosurgical excision procedure in HIV-1-infected and non-infected women.
Hoa Nguyen Lam, Huyen Suong Ho Thi et al.
F.Behnamfar Gynecology Oncology Fellow Professor
QUIZ QUESTIONS 1) WHAT ARE THE TWO TYPES OF CERVICAL CANCER?
Management of the Abnormal Pap Smear.
Cervical Screening for Dysplasia and Cancer in Patients with HIV
Neoplasia of the cervix
Cervical excisional treatment of young women: A population-based study
SH-sheikhhasani Gyn-oncologist
Fig. 1. Flowchart of inclusion and exclusion criteria of the study population.ASC-US, atypical squamous cells of undetermined significance; CIN, cervical.
Presentation transcript:

In the Name of God

Screening of Cervical Cancer Pap smear and colposcopy F.Behnamfar Gynecology Oncology Fellowship Associate Professor Isfahan University of medical Sciences Isfahan University of medical Sciences

Epidemiology and Risk Factors Second most common cancer among women worldwide 83% of cases in developing countries 12,200 new cases and 4210 cancer related deaths in USA, million pap tests are performed in the US each year,3.5 million abnormal and 2.5 million colposcopy each year

Natural History External genital warts,1% Cervical intraepithelial neoplasia (CIN) Slow malignant transformation Slow malignant transformation long latency period for cervical cancer long latency period for cervical cancer CIN I,II,II CIN I,II,II

Papanicolaou Smear Conventional Thin layer,liquid based Cytology report includes Adequacy General categorization Epithelial cell abnormality Glandular cell abnormality

Abnormal pap smear ASCUS LSIL HSIL

Cytologic diagnosis Pap test yeilds cytologic diagnosis Diagnosis of CIN or cervical cancer requiers a tissue sample for histologic diagnosis

Pap Test Screening test rather than diagnostic test Sensitivity and specificity Liquid based/ conventional pap smear Effectiveness No pap in last five years, risk of cervical cancer is threefold 90% risk reduction

Follow up of abnormal cytology ASCUSASC-H AGC Risk for CIN 2-3 and AIS,serious precursor of adenocarcinoma LSIL(CIN I- HPV infection) HSIL

HPV test High risk HPV,16-18… Transient Infection Screeningtriage

Screening Parameters Initial screening Discontinuing screening Frequency of screening Perior hysterectomy HPV Vaccination

THANKS

Management HPV and CIN 1:Follow up(60-85% regress spontaneously in 2 years) CIN 2-3: LEEP (loop electro surgical exision of T zone) Cryo,Laser,Hysterectomy Cryo,Laser,Hysterectomy

Pap smear 79% reduction in cervical cancer 47-62%sensitivity(30% of cervical cancers…) Liquid based,80% sensitive Auto prep Inadequacy,repeat in 6-12 months Inadequacy,repeat in 6-12 monthsGenerally: negative for intraepithelial lesion Epithelial cell abnormality Other:glandular cell abnormalities

Screening Beginning at 21y,or 3y after onset of sexual activity Can stop at 70 Yearly< years>30(if pap&HPV neg) HPV>99%sensitive

Cervical Cancer 3 rd most common gyn cancer in USA Squamous most common Adenocarcinoma increasing Clinically staged Risk factors Evaluation(vaginal bleeding,post coital,irregular, post menopausal) Discharge Obvious tumor Suspicious,colposcoy biopsy,conization

Staging Stage I(1a1, 1a2,1b1, 1b2) StageIIStageIIIStageIV